Compared to the IV infusion of the blockbuster cancer drug Keytruda, subcutaneous Keytruda can cut the time spent in ...

MSD has opened a $1bn facility in Durham located in the US state of North Carolina, to increase vaccine manufacturing capacity.

MSD has entered an exclusive licence agreement with Hengrui Pharma for the oral small molecule Lp(a) inhibitor, HRS-5346.

MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.

MSD has agreed to pay up to $610 million to acquire Caraway Therapeutics, a Cambridge, Massachusetts biotech focusing on neurodegenerative disorders and rare diseases. The big pharma, known as ...

The decision was influenced by the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use.

BEIJING, March 27 (Xinhua) -- Multinational pharmaceutical firms, particularly U.S. giants, are increasingly recognizing China's burgeoning innovative drug sector as a strategic goldmine to bolster ...